The Biopharmaceutical Classification System: A Comprehensive review
Authors/Creators
Description
The Biopharmaceutical Classification System (BCS) is a scientific framework that categorizes drug substances according to their aqueous solubility and intestinal permeability, two key determinants of oral drug absorption from immediate-release solid dosage forms. By integrating dissolution characteristics with permeability data, BCS provides a mechanistic basis for understanding in vivo drug performance and supports rational formulation development. This review outlines the fundamental principles, objectives, regulatory guidance, and defining characteristics of BCS classes, as well as their practical significance in pharmaceutical research and development. It also discusses challenges associated with poor solubility and variable in vivo disposition, which remain major barriers in drug development. BCS classifies drugs into four categories: Class I (high solubility, high permeability), Class II (low solubility, high permeability), Class III (high solubility, low permeability), and Class IV (low solubility, low permeability). These classifications guide formulation strategies and enable the design of optimized dosage forms using predictive, science-based approaches rather than empirical methods. Furthermore, BCS concepts play a critical role in regulatory decision-making, including applications for New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), biowaivers, and scale-up and post-approval manufacturing changes. By applying BCS principles, pharmaceutical companies can streamline development processes, reduce unnecessary in vivo studies, and achieve significant savings in time and cost while ensuring product quality and therapeutic efficacy.